Paricalcitol Attenuates Metabolic Syndrome-Associated Heart Failure through Enhanced Mitochondrial Fusion.

Hina Lateef NizamiParmeshwar B KatarePankaj PrabhakarRamu AdelaSoumalya SarkarSudheer AravaPraloy ChakrabortySubir K MaulikSanjay K Banerjee

Published in: Oxidative medicine and cellular longevity (2022)

Paricalcitol reverses cardiac dysfunction in rats with metabolic syndrome by enhancing mitochondrial fusion. We demonstrate repurposing potential of the drug currently used in end-stage kidney disease.

Keyphrases

metabolic syndrome
oxidative stress
heart failure
left ventricular
insulin resistance
uric acid
cardiovascular risk factors
emergency department
atrial fibrillation
adverse drug
cardiovascular disease
adipose tissue
drug induced
risk assessment
electronic health record
drug discovery